Zynex(US:ZYXI)2025-03-11 21:50Company Overview - Zynex's share price was $10.10 as of July 22, 2024, with a market capitalization of $321 million[4] - The company's trailing twelve months (TTM) revenue as of June 30, 2024, was $193 million, with a gross margin of 80% and a net income of $6 million[4] - Zynex has $30.8 million in cash and cash equivalents as of June 30, 2024[4] - Insider holdings account for 51.5% of outstanding shares[4] Market and Growth - Zynex operates in an addressable market exceeding $4.6 billion, presenting high growth opportunities[5] - The electrotherapy market size is $950 million, excluding stroke treatment[10, 11] - The patient monitoring market size is $3.6 billion, excluding sepsis[10, 11] - The company's revenue has grown at a 4-year compound annual growth rate (CAGR) of 42%[5] Financial Performance - Zynex's TTM EBITDA is $22.4 million[5] - In 2023, 68% of Zynex's revenue came from supplies[15] - The company's revenue increased from $45.5 million in 2019 to $184.3 million in 2023, representing a 42% CAGR[50] - Zynex is targeting sales reps to achieve >$1 million in revenue per rep[36]